Cited by 889Cancer therapeutics and mechanismsBioactive Compounds and Antitumor AgentsMetal complexes synthesis and properties

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Open access

Tewey, K M, Chen, G L, Nelson, E M, Liu, L F·1984·Journal of Biological Chemistry

DOI 10.1016/s0021-9258(17)47282-6

Open this paper in CoChat — free account

Abstract

Many intercalative antitumor drugs have been shown to induce reversible protein-linked DNA breaks in cultured mammalian cells. Using purified mammalian DNA topoisomerase II, we have demonstrated that the antitumor drugs ellipticine and 2-methyl-9-hydroxyellipticine (2-Me-9-OH-E+) can produce reversible protein-linked DNA breaks in vitro. 2-Me-9-OH-E+ which is more cytotoxic toward L1210 cells and more active against experimental tumors than ellipticine is also more effective in stimulating DNA cleavage in vitro. Similar to the effect of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) on topoisomerase II in vitro, the mechanism of DNA breakage induced by ellipticines is most likely due to the drug stabilization of a cleavable complex formed between topoisomerase II and DNA. Protein denaturant treatment of the cleavable complex results in DNA breakage and covalent linking of one topoisomerase II subunit to each 5'-end of the cleaved DNA. Cleavage sites on pBR322 DNA produced by ellipticine or 2-Me-9-OH-E+ treatment mapped at the same positions. However, many of these cleavage sites are distinctly different from those produced by the antitumor drug m-AMSA which also targets at topoisomerase II. Our results thus suggest that although mammalian DNA topoisomerase II may be a common target of these antitumor drugs, drug-DNA-topoisomerase interactions for different antitumor drugs may be different.

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(17)47282-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

DNA Topoisomerases
Gellert, M. F. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.004311 · Cited by 990
DNA Gyrase and the Supercoiling of DNA
Cozzarelli, N. R. (1980) · Science · doi:10.1126/science.6243420 · Cited by 720
DNA Modification and Cancer
Waring, M. J. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.001111 · Cited by 690
The Anticancer Agent Adriamycin Can Be Actively Cytotoxic Without Entering Cells
Triton, T. R., & Yee, G. K. (1982) · Science · doi:10.1126/science.7089561 · Cited by 573
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 561
Self-citation
Cleavage of DNA by mammalian DNA topoisomerase II.
Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., & Chen, G. L. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43815-4 · Cited by 534
Self-citation
Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break.
Liu, L. F., Liu, C.-C., & Alberts, B. (1980) · Cell · doi:10.1016/s0092-8674(80)80046-8 · Cited by 486
Self-citation
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., & Kohn, K. W. (1981) · Biochemistry · doi:10.1021/bi00526a006 · Cited by 374
A homogeneous type II DNA topoisomerase from HeLa cell nuclei.
Miller, K. G., Liu, L. F., & Englund, P. T. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52552-2 · Cited by 359
Self-citation
Terminal stages of SV40 DNA replication proceed via multiply intertwined catenated dimers
Sundin, O. H., & Varshavsky, A. J. (1980) · Cell · doi:10.1016/0092-8674(80)90118-x · Cited by 354

Show all 39 references

Research works printed but not linked: 3

Zwelling, 1982, Cancer Res., 42, 2687
Burr-Furlong, 1978, Cancer Res., 38, 1329
Pommier, 1982, Biochem. Biophys. Res. Commun., 77, 1150

Sorted by citations

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,242
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Self-citation
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y. G., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,842
“Inhibition of Top2 catalytic activity without trapping cleavage complexes is also observed for DNA intercalators at drug concentrations that alter DNA structure, thereby preventing Top2 from binding DNA (step 1 in Figure 5A) or from forming Top2cc (step 3) (Pommier et al., 1984; Tewey et al., 1984).”
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2607 · Cited by 1,861
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,542
Self-citation
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,032
Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Kaufmann, S. H. (1989) · PubMed · Cited by 922
Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites
Cockerill, P. N., & Garrard, W. T. (1986) · Cell · doi:10.1016/0092-8674(86)90761-0 · Cited by 881
DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 855
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. G. (2012) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 867
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Self-citation
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
DNA Topoisomerases: Essential Enzymes and Lethal Targets
Chen, A. Y., & Liu, L. F. (1994) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.34.040194.001203 · Cited by 737
Self-citation
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G. N., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 608
Anaphase is initiated by proteolysis rather than by the inactivation of maturation-promoting factor
Holloway, S. L., Glotzer, M., King, R. W., & Murray, A. W. (1993) · Cell · doi:10.1016/0092-8674(93)90364-v · Cited by 566
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex
Hertzberg, R., Caranfa, M. J., & Hecht, S. M. (1989) · Biochemistry · doi:10.1021/bi00437a018 · Cited by 552
Nuclear reconstitution in vitro: Stages of assembly around protein-free DNA
Newport, J. W. (1987) · Cell · doi:10.1016/0092-8674(87)90424-7 · Cited by 536
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II
Varga‐Weisz, P., Wilm, M. S., Bonte, E. J., Dumas, K., Mann, M., & Becker, P. B. (1997) · Nature · doi:10.1038/41587 · Cited by 513
Tumor Cell Death Induced by Topoisomerase-Targeting Drugs
Li, T., & Liu, L. F. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.53 · Cited by 509
Self-citation
hMre11 and hRad50 Nuclear Foci Are Induced During the Normal Cellular Response to DNA Double-Strand Breaks †
Maser, R. S., Monsen, K. J., Nelms, B. E., & Petrini, J. H. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.6087 · Cited by 499
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
Burden, D. A., & Osheroff, N. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00132-8 · Cited by 503
Localization of topoisomerase II in mitotic chromosomes.
Earnshaw, W. C., & Heck, M. M. S. (1985) · The Journal of Cell Biology · doi:10.1083/jcb.100.5.1716 · Cited by 495
Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
Chen, G. L., Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90729-5 · Cited by 492
Self-citation
Human topoisomerases and their roles in genome stability and organization
Pommier, Y. G., Nussenzweig, A., Takeda, S., & Austin, C. A. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00452-3 · Cited by 493
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., & Pommier, Y. G. (1989) · PubMed · Cited by 449
Topoisomerase-targeting antitumor drugs
D’Arpa, P., & Liu, L. F. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90041-3 · Cited by 434
Self-citation
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
D’Arpa, P., Beardmore, C., & Liu, L. F. (1990) · PubMed · Cited by 425
Self-citation
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T. A., Kerkhoven, R. M., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 431
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2020) · FEBS Journal · doi:10.1111/febs.15583 · Cited by 442
Chromosome assembly in vitro: Topoisomerase II is required for condensation
Adachi, Y., Luke, M. M., & Laemmli, U. K. (1991) · Cell · doi:10.1016/0092-8674(91)90215-k · Cited by 390
Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage
Anderson, L., Henderson, C., & Adachi, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1719-1729.2001 · Cited by 367
Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
Fortune, J. M., & Osheroff, N. (2000) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(00)64006-0 · Cited by 369
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm, C., Covey, J. M., Kerrigan, D., & Pommier, Y. G. (1989) · PubMed · Cited by 366
Discovery of podophyllotoxins
Imbert, T. (1998) · Biochimie · doi:10.1016/s0300-9084(98)80004-7 · Cited by 351
Idarubicin
Hollingshead, L. M., & Faulds, D. M. (1991) · Drugs · doi:10.2165/00003495-199142040-00010 · Cited by 346
Disassembly of the nucleus in mitotic extracts: Membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes
Newport, J. W., & Spann, T. P. (1987) · Cell · doi:10.1016/0092-8674(87)90425-9 · Cited by 344
DNA Topoisomerases: Enzymes That Control DNA Conformation
Vosberg, H.-P. (1985) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-70227-3_2 · Cited by 321
Recent studies of DNA topoisomerases
Wang, J. C. (1987) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(87)90040-6 · Cited by 321
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II
Super, H. J. G., McCabe, N., Thirman, M., Larson, R. A., Beau, M. M. L., Pedersen-Bjergaard, J., Philip, P., Diaz, M., & Rowley, J. (1993) · Blood · doi:10.1182/blood.v82.12.3705.3705 · Cited by 320
Preferential, cooperative binding of DNA topoisomerase II to scaffold‐associated regions.
Adachi, Y., Käs, E., & Laemmli, U. K. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08582.x · Cited by 316
Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro.
Yang, L., Wold, M. S., Li, J. J., Kelly, T. J., & Liu, L. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.4.950 · Cited by 289
Self-citation
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.
Zhang, H., Wang, J. C., & Liu, L. F. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1060 · Cited by 284
Self-citation
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.
Drake, F. H., Zimmerman, J., McCabe, F. L., BARTUS, H. F., Per, S., Sullivan, D. M., Ross, W., Mr, M., Johnson, R., & Crooke, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49317-9 · Cited by 278
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Marinello, J., Delcuratolo, M., & Capranico, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113480 · Cited by 280
“Initial findings clearly showed that anticancer Top2 poisons of different structural families induce DNA cleavage in a sequence-selective manner, which can be revealed experimentally as drug-specific cleavage intensity patterns in sequencing gels [47,48,57].”
Background
The Clinical Pharmacology of Etoposide and Teniposide
CLARK, P. I., & Slevin, M. L. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198712040-00001 · Cited by 261
Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
Deffie, A. M., Batra, J. K., & Goldenberg, G. J. (1989) · PubMed · Cited by 261
Interfacial inhibitors: targeting macromolecular complexes
Pommier, Y. G., & Marchand, C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 260
Mechanistic Aspects of DNA Topoisomerases
Maxwell, A., & Gellert, M. F. (1986) · Advances in protein chemistry · doi:10.1016/s0065-3233(08)60526-4 · Cited by 259
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2015) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 265
Production and biological activity of rebeccamycin, a novel antitumor agent.
BUSH, J. A., Long, B. H., Catino, J. J., & Bradner, W. T. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.668 · Cited by 252
Biochemical basis for the interactions of type I and type II topoisomerases with DNA
Osheroff, N. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90108-3 · Cited by 252
A consensus sequence for cleavage by vertebrate DNA topoisomerase II
Spitzner, J. R., & Muller, M. T. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.12.5533 · Cited by 249
Cytotoxicity, Post-Treatment Recovery, and Selectivity Analysis of Naturally Occurring Podophyllotoxins from Bursera fagaroides var. fagaroides on Breast Cancer Cell Lines
Peña-Morán, O. A., Villarreal, M., Álvarez, L., Meneses‐Acosta, A., & Rodríguez-López, V. (2016) · Molecules · doi:10.3390/molecules21081013 · Cited by 248
Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase
Shamu, C., & Murray, A. W. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.117.5.921 · Cited by 237
Drosophilatopoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site
Sander, M., & Hsieh, T. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.4.1057 · Cited by 234
Topoisomerase II does not play a scaffolding role in the organization of mitotic chromosomes assembled in Xenopus egg extracts.
Hirano, T., & Mitchison, T. J. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.120.3.601 · Cited by 233
Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group.
Breslow, N. E., Takashima, J. R., Whitton, J. A., Moksness, J., D’Angio, G. J., & Green, D. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1851 · Cited by 223
Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide
Osheroff, N. (1989) · Biochemistry · doi:10.1021/bi00441a005 · Cited by 226
Sequence-Selective DNA Recognition: Natural Products and Nature’s Lessons
Tse, W. C., & Boger, D. L. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.08.012 · Cited by 227
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley, A. L., Liu, L. F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F. C., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 225
Self-citation
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
Danks, M. K., Yalowich, J. C., & Beck, W. T. (1987) · PubMed · Cited by 225
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto, Y., Tsukahara, S., Oh‐hara, T., Isoe, T., & TSURUO, T. (1990) · PubMed · Cited by 223
Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs.
Shapiro, T. A., & Englund, P. T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.3.950 · Cited by 222
beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin.
Li, C. J., Averboukh, L., & Pardee, A. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41552-9 · Cited by 219
Effects of CPT‐11 in combination with other anti‐cancer agents in culture
Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Indue, Y., Yosnida, M., Sakamoto, S., & Miura, Y. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500420 · Cited by 218
Mapping the active site tyrosine of Escherichia coli DNA gyrase.
Horowitz, D. S., & Wang, J. C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61193-7 · Cited by 217
The DNA Intercalating Alkaloid Cryptolepine Interferes with Topoisomerase II and Inhibits Primarily DNA Synthesis in B16 Melanoma Cells
Bonjean, K., Pauw-Gillet, M. C. D., Defresne, M. P., Colson, P., Houssier, C., Dassonneville, L., Bailly, C., Greimers, R., Wright, C. W., Quetin‐Leclercq, J., et al. (1998) · Biochemistry · doi:10.1021/bi972927q · Cited by 216
Mechanism of quinolone inhibition of DNA gyrase
Shen, L. L., Kohlbrenner, W. E., Weigl, D., & Baranowski, J. L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)81708-8 · Cited by 215
Induction of mammalian topoisomerase ii dependent dna cleavage by nonintercalative flavonoids, genistein and orobol
Yoshinori, Y., Kawada, S., & Nakano, H. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90153-c · Cited by 215
Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells
Swift, L. H., & Golsteyn, R. M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033403 · Cited by 230
Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.
Halligan, B. D., Edwards, K. A., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89578-3 · Cited by 212
Self-citation
Camptothecin, A Specific Inhibitor of Type I DNA Topoisomerase, Induces DNA Breakage at Replication Forks
Avemann, K., Knippers, R., Koller, T., & Sogo, J. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.8.3026 · Cited by 211
Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors
Pommier, Y. G., Pharm, D., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, É., Kohlhagen, G., & Kohn, K. W. (1994) · Cancer Investigation · doi:10.3109/07357909409021413 · Cited by 208
DNA End Resection: Nucleases Team Up with the Right Partners to Initiate Homologous Recombination
Ćejka, P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.675942 · Cited by 208
DNA Topoisomerases as Anticancer Drug Targets
Schneider, E., Hsiang, Y. H., & Liu, L. F. (1990) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60342-7 · Cited by 193
Self-citation
DNA topoisomerases as targets for cancer therapy
Ross, W. E. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90273-4 · Cited by 190
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
Geisberg, C. A., & Sawyer, D. B. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0146-y · Cited by 189
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Long, B. H., Musial, S. T., & Brattain, M. G. (1985) · PubMed · Cited by 188
Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I
CHOWDHURY, A. R., Sharma, S., Mandal, S., Goswami, A., Mukhopadhyay, S., & Majumder, H. K. (2002) · Biochemical Journal · doi:10.1042/bj20020098 · Cited by 186
Genotoxicity of benzene and its metabolites
Whysner, J. A., Reddy, M. V., Ross, P. M., Mohan, M., & Lax, E. A. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(03)00053-x · Cited by 178
In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics.
Käs, E., & Laemmli, U. K. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05103.x · Cited by 176
Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells.
Pommier, Y. G., Zwelling, L. A., Kao-Shan, C. S., Whang‐Peng, J., & Bradley, M. O. (1985) · PubMed · Cited by 174
Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage–induced apoptosis
Tepper, A. D., de Vries, E., BLITTERSWIJK, W. J. V., & Borst, J. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5457 · Cited by 173
Therapy‐related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
Smith, M. A., Rubinstein, L., & Ungerleider, R. S. (1994) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950230205 · Cited by 171
The Secondary Leukemias: Challenges and Research Directions
Smith, M. A., McCaffrey, R. P., & Karp, J. E. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.7.407 · Cited by 166
Proliferation dependence of topoisomerase II-mediated drug action
Sullivan, D. M., Glisson, B. S., Hodges, P. K., Smallwood-Kentro, S., & Ross, W. E. (1986) · Biochemistry · doi:10.1021/bi00356a060 · Cited by 166
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin
Qiao, X., van der Zanden, S. Y., Wander, D. P. A., Borràs, D., Song, J., Li, X., van Duikeren, S., van Gils, N., Rutten, A. P., van Herwaarden, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922072117 · Cited by 167
Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Fry, A. M., Chresta, C. M., Davies, S. M., Walker, M. C., Harris, A. L., Hartley, J. A., Masters, J. R., & Hickson, I. D. (1991) · PubMed · Cited by 163
Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.
Davies, S. M., Robson, C. N., Davies, S. L., & Hickson, I. D. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77896-x · Cited by 163
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg, B. Y., Danks, M. K., Beck, W. T., & Suttle, D. P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7654 · Cited by 159
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
Jong, D. S., Zijlstra, J. G., de Vries, E. G. E., & Mulder, N. H. (1990) · PubMed · Cited by 159
Molecular and cellular mechanisms of anthracycline cardiotoxicity
Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0005-5 · Cited by 158
“In the late 1970s and early 1980s, it was discovered that anthracyclines would induce strand breaks in DNA of L1210 leukemic cells through association with proteins later identified to be topoisomerase II [27].”
Background
G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer
Oshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082921 · Cited by 158
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes
Ratain, M. J., & Rowley, J. D. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058121 · Cited by 156
“Inhibitors of topoisomerase II include both the intercalators [45] and non-intercalating epipodophyllotoxins [46].”
Background
Principles and practice of DNA filter elution
Kohn, K. W. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90022-e · Cited by 155
Chronic daily administration of oral etoposide--a phase I trial.
Hainsworth, J. D., Johnson, D. H., Redlin-Frazier, S., & Greco, F. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.3.396 · Cited by 150
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential
Childress, E. S., Alexopoulos, S. J., Hoehn, K. L., & Santos, W. L. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01182 · Cited by 148

Authors: Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F.
Affiliations: Johns Hopkins University (US)
ORCID: Liu, L F
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 1984-07
Volume: 259
Issue: 14
Pages: 9182-9187
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1016/s0021-9258(17)47282-6
OpenAlex: W1514525963
Cited by: 887
References: 39
Citations by year: 2026: 2 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 19 · 2015: 14 · 2014: 14 · 2013: 16 · 2012: 14
FWCI: 15.02
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 13270 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: topoisomerase II, epipodophyllotoxins, etoposide, doxorubicin, cleavable complex, drug-enzyme interaction, nalidixic acid, DNA gyrase, cytotoxicity mechanism
MeSH terms: Alkaloids, Animals, Antineoplastic Agents, Cattle, DNA, DNA Topoisomerases, Type II, DNA Topoisomerases, Type I, DNA, Viral, Ellipticines, HeLa Cells, Humans, Intercalating Agents, Kinetics, Osmolar Concentration, Plasmids, Protein Binding, Thymus Gland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks